New advances and potential therapies for the treatment of asthma

BioDrugs

Volumn 18, Issue 4, 2004, Pages 211-223

  Belvisi, Maria G ^a   Hele, David J ^a   Birrell, Mark A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADALIMUMAB; ADENOSINE RECEPTOR AFFECTING AGENT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; ETANERCEPT; FORMOTEROL; INFLIXIMAB; LIPOXIN; LOTEPREDNOL ETABONATE; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MOMETASONE FUROATE; MONTELUKAST; N (1 HYDROXY 2 NAPHTHOYL)ARGINYLPROLINAMIDE; OMALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PRANLUKAST; ROFLUMILAST; SALMETEROL; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ASTHMA; B LYMPHOCYTE; BASOPHIL; CATARACT; CHEMOTAXIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG RECEPTOR BINDING; DRUG TARGETING; DYSPHONIA; ENZYME INHIBITION; EOSINOPHIL; HUMAN; IMMUNOTHERAPY; INFLAMMATORY CELL; MAST CELL; MEDIATOR; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; THRUSH;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; IMMUNOTHERAPY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES;

EID: 3843118877     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418040-00001     Document Type: Review

References (142)

1. Pahl A, Szelenyi I. Asthma therapy in the new millennium. Inflamm Res 2002; 51: 273-82
2. Rutten Van Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 2001; 19: 1-6
3. Global Initiative for Asthma, Global strategy for asthma management and prevention. NHLBIAVHO Workshop Report. National Institutes of Health. National Heart Lung and Blood Institute. Publication number 02-3659 2002: 16
4. Bjermer L. History and future perspectives of treating asthma as a systemic and small airway disease. Respir Med 2001; 95: 703-19
5. Holtzman MJ. Drug development for asthma. Am J Respir Cell Mol Biol 2003; 29: 163-71
6. Holt PG, Yabuhara A, Prescott S, et al. Allergen recognition in the origin of asthma. Ciba Found Symp 1997; 206: 35-49
7. Norman PS. Immunotherapy: past and present. J Allergy Clin Immunol 1998; 102: 1-10
8. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-75
9. Hansel TT, Barnes PJ. Novel drugs for treating asthma. Curr Allergy Asthma Rep 2001; 1: 164-73
10. Larche M. Anti-T-cell strategies in the treatment of allergic disease. Allergy 2002; 57: 20-3
11. Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002 Jul 6; 360: 47-53
12. Riese RJ, Mitchell RN, Villadangos JA, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998 Jun 1; 101 (11): 2351-63
13. Shi GP, Bryant RA, Riese R, et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000 Apr 3; 191 (7): 1177-86
14. Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T cell proliferation and interleukin 10 secretion. Nat Med 2001; 5: 1365-9
15. Gonzalo JA, Tian J, Delaney T, et al. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat Immunol 2001; 2: 597-604
16. Tesciuba AG, Subudhi S, Rother RP, et al. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J Immunol 2001; 167: 1996-2003
17. Van Oosterhout AJ, Hofstra CL, Shields R. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in murine model of allergic asthma. Am J Respir Cell Mol Biol 1997; 17: 386-92
18. Deurloo DT, Van Esch BC, Hofstra CL, et al. CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am J Respir Cell Mol Biol 2001; 25: 751-60
19. Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995 Jan; 95 (1 Pt 1): 133-5
20. Martin RJ, Boguniewicz M, Henson JE, et al. The effects of inhaled Interferon gamma in normal human airways. Am Rev Respir Dis 1993 Dec; 148 (6 Pt 1): 1677-82
21. Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5
22. Silverman ES, Drazen JM. Immunostimulatory DNA for asthma: better than eating dirt. Am J Respir Cell Mol Biol 2003 Jun; 28 (6): 645-7
23. Jain VV, Businga TR, Kitagaki K, et al. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol 2003 Nov; 285 (5): 4137-46
24. Kline JN. DNA therapy for asthma. Curr Opin Allergy Clin Immunol 2002; 2: 69-73
25. Uhlmann E, Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel 2003 Mar; 6 (2): 204-17
26. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001 Nov 1; 98 (9): 2736-44
27. Zuany-Amorim C, Manlius C, Trifilieff A, et al. Long-term protective and antigen-specific effect of heat-killed Mycobacterium vaccae in a murine model of allergic pulmonary inflammation. J Immunol 2002 Aug 1; 169 (3): 1492-9
28. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963-70
29. Tomkinson A, Duez C, Cieslewicz G, et al. A murine IL-4 receptor antagonist that inhibits IL-4 and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001; 166: 5792-800
30. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998 Dec 18; 282 (5397): 2258-61
31. Tomkinson A, Duez C, Lahn M, et al. Adoptive transfer of T cells induces airway hyperresponsiveness independently of airway eosinophilia but in a signal transduction and activator of transcription 6-dependent manner. J Allergy Clin Immunol 2002 May; 109 (5): 810-6
32. Mathew A, Medoff BD, Carafone AD, et al. Cutting edge: Th2 cell trafficking into the allergic lung is dependent on chemoattractant receptor signaling. J Immunol 2002 Jul 15; 169 (2): 651-5
33. Moser M. Regulation of Th1/Th2 development by antigen-presenting cells in vivo. Immunobiology 2001 Dec; 204 (5): 551-7
34. Mathew A, MacLean JA, DeHaan E, et al. Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. J Exp Med 2001 May 7; 193 (9): 1087-96
35. White JR, Lee JM, Dede K, et al. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. J Biol Chem 2000; 275: 626-31
36. Sabroe I, Peck MJ, Van Keulen BJ, et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem 2000; 275: 985-92
37. Wacker DA, Santella III JB, Gardner DS, et al. CCR3 antagonists: a potential new therapy for the treatment of asthma: discovery and structure-activity relationship. Bioorg Med Chem Lett 2002; 12: 1785-9
38. Warrior U, McKeegan EM, Rottinghaus SM, et al. Identification and characterisation of novel antagonists of the CCR3 receptor. J Biomol Screen 2003 Jun; 8 (3): 324-31
39. D'ambrosio D, Mariani M, Panina-Bordignon P, et al. Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med 2001; 164: 1266-75
40. Gater P, Satjawatcharaphong C, Staley C, et al. Effect of orally active CCR3 antagonists in animal models of allergic airway inflammation [abstract]. Am J Respir Crit Care Med 2002; 165: A313
41. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990 Oct 11; 323 (15): 1033-9
42. Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2001; 356: 2144-8
43. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199-204
44. Kips JC, Tournoy KG, Pauwels RA. New asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Eur Respir J 2001; 17: 499-506
45. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized antihuman interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655-9
46. Foster PS, Martinez-Moczygemba M, Huston DP, et al. Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Ther 2002; 94: 253-64
47. Kay AB, Menzies-Gow A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003 Jun 15; 167 (12): 1586-7
48. Sun Q, Jones K, McClure B, et al. Simultaneous antagonism of IL-5, granulocyte-macrophage colony stimulating factor, and IL-3 stimulation of human eosinophils by targeting the common cytokine binding site of their receptors. Blood 1999; 94: 1943-51
49. Ramshaw HS, Woodcock JM, Bagley CJ, et al. New approaches in the treatment of asthma. Immunol Cell Biol 2001; 79: 154-9
50. Abraham WM, Gill A, Ahmed A, et al. A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med 2000 Aug; 162 (2 Pt 1): 603-11
51. Kudlacz E, Whitney C, Andresen C, et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. J Pharmacol Exp Ther 2002 May; 301 (2): 747-52
52. Koo GC, Shah K, Ding GJ, et al. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am J Respir Crit Care Med 2003 May 15; 167 (10): 1400-9
53. Miller DH, Khan OA, Sheremata WA, et al. International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003 Jan 2; 348 (1): 15-23
54. Tomioka M, Ida S, Shindoh Y, et al. Mast cells in bronchoalveolar lumen of patients with bronchial asthma. Am Rev Respir Dis 1984 Jun; 129 (6): 1000-5
55. Brewster CE, Howarth PH, Djukanovic R, et al. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990 Nov; 3 (5): 507-11
56. Tumas DB, Chan B, Werther W, et al. Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitisation. Allergy Clin Immunol 2001; 107: 1025-33
57. Berger WE. Monoclonal anti-IgE antibody, a novel therapy for allergic airways disease. Ann Allergy Asthma Immunol 2002; 8: 152-60
58. D'Amato G. Therapy of allergic bronchial asthma with omalizumab: an anti-IgE monoclonal antibody. Expert Opin Biol Ther 2003; 3 (2): 371-6
59. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61
60. Holgate S, Bousquet J, Wenzel S, et al. Omalizumab improves disease control in patients at high risk of serious asthma-related morbidity and mortality [abstract]. Am J Respir Crit Care Med 2002; 165: A187
61. Bousquet J, Holgate S, Wenzel S, et al. Omalizumab reduces the incidence and frequency of exacerbations in patients at high risk of serious asthma-related morbidity and mortality [abstract]. Am J Respir Crit Care Med 2002; 165: A187
62. Wenzel S, Bousquet J, Holgate S, et al. Patients with more severe allergic asthma gain greatest relative benefit from omalizumab therapy [abstract]. Am J Respir Crit Care Med 2002; 165: A215
63. Liu MC, Hubbard WC, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991 Jul; 144 (1): 51-8
64. Knight DA, Stewart GA, Thompson PJ. Histamine tachyphylaxis in human airway smooth muscle: the role of H2-receptors and the bronchial epithelium. Am Rev Respir Dis 1992 Jul; 146 (1): 137-40
65. Hele DJ, Birrell MA, Webber SE, et al. Mediator involvement in antigen-induced bronchospasm and microvascular leakage in the airways of ovalbumin sensitized Brown Norway rats. Br J Pharmacol 2001 Jan; 132 (2): 481-8
66. Shelhamer JH, Marom Z, Kaliner M. Immunologic and neuropharmacologic stimulation of mucous glycoprotein release from human airways in vitro. J Clin Invest 1980 Dec; 66 (6): 1400-8
67. Panettieri RA, Yadvish PA, Kelly AM, et al. Histamine stimulates proliferation of airway smooth muscle and induces c-fos expression. Am J Physiol 1990 Dec; 259 (6 Pt 1): L365-71
68. Loring SH, Drazen JM, Snapper JR, et al. Vagal and aerosol histamine interactions on airway responses in dogs. J Appl Physiol 1978 Jul: 45 (1): 40-4
69. Whicker SD, Armour CL, Black JL. Responsiveness of bronchial smooth muscle from asthmatic patients to relaxant and contractile agonists. Pulm Pharmacol 1988; 1 (1): 25-31
70. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003 Jul; 112 (1): 15-22
71. Van Ganse E, Kaufman L, Derde MP, et al. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997 Oct; 10 (10): 2216-24
72. Gelfand EW. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am J Med 2002 Dec 16; 113 Suppl. 9A: 2S-7S
73. McMillan RM. Leukotrienes in respiratory disease. Paediatr Respir Rev 2001 Sep; 2 (3): 238-44
74. Holgate ST, Peters-Golden M, Panettieri RA, et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function and remodeling. J Allergy Clin Immunol 2003; 111: S18-36
75. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002; 324: 1545-52
76. Borish L. The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann Allergy Asthma Immunol 2002; 88: 16-22
77. Creticos P, Knobil K, Edwards LD, et al. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol 2002; 88: 401-9
78. Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103: 1075-80
79. Barnes PJ. Anti-leukotrienes: here to stay? Curr Opin Pharmacol 2003; 3: 257-63
80. Hart PH. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 2001; 79: 149-53
81. Akers IA, Parsons M, Hill MR, et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am J Physiol Lung Cell Mol Physiol 2000; 278: L193-201
82. Sylvin H, Dahlback M, Van Der Ploeg I, et al. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitised to Ascaris suum. Clin Exp Allergy 2002; 32: 967-71
83. Wright CD, Havill AM, Middleton SC, et al. Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-[4-[3- cabamimidoyl-benzenesulfonylamino)-methyl]-phenoxy-pentane (AMG-126737). Biochem Pharmacol 1999; 58: 1989-96
84. Oh SW, Pae CI, Lee DK, et al. Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol 2002; 168: 1992-2000
85. Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-Activated Receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002 Nov 1; 169 (9): 5315-21
86. Krishna MT, Chauhan A, Little L, et al. Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. J Allergy Clin Immunol 2001; 107: 1039-45
87. Fozard JR, Hannon JP. Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm Pharmacol Ther 1999; 12: 111-4
88. Fozard JR. The case for a role of adenosine in asthma: almost convincing? Curr Opin Pharmacol 2003; 3: 264-9
89. Holgate ST. Adenosine: a key effector molecule of asthma or just another mediator? Am J Physiol Lung Cell Mol Physiol 2002; 282: L167-8
90. Ohta A, Sitkowsky M. Role of G-protein-coupled adenosine receptors in down regulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-20
91. Fozard JR, McCarthy C. Adenosine receptor ligands as potential therapeutics in asthma. Curr Opin Investig Drugs 2002; 3: 69-77
92. Sandrasagra A, Leonard SA, Tang L, et al. Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev 2002; 12: 177-81
93. Fozard JR, Ellis KM, Villela Ddantas MF, et al. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002; 438: 183-8
94. GlaxoSmithKline PLC. Product development pipeline February 2001. Company brochure. Stewerage, UK: GlaxoSmithKline PLC, 2001 Feb 22
95. Ezeamuzie CI. Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline. Biochem Pharmacol 2001; 61: 1551-9
96. Muller CE. Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 2003; 3 (4): 445-62
97. Armour CL, Johnson PR, Alfredson ML, et al. Characterization of contractile prostanoid receptors on human airway smooth muscle. Eur J Pharmacol 1989 Jun 20; 165 (2-3): 215-22
98. Walters EH, Davies BH. Dual effect of prostaglandin E2 on normal airways smooth muscle in vivo. Thorax 1982 Dec; 37 (12): 918-22
99. Belvisi MG, Saunders M, Yacoub M, et al. Expression of cyclooxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth. Br J Pharmacol 1998 Nov; 125 (5): 1102-8
100. Pavord ID, Wong CS, Williams J, et al. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993 Jul; 148 (1): 87-90
101. Costello JF, Dunlop LS, Gardiner PJ. Characteristics of prostaglandin induced cough in man. Br J Clin Pharmacol 1985 Oct; 20 (4): 355-9
102. Coleman RA, Sheldrick RL. Prostanoid-induced contraction of human bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol 1989 Mar; 96 (3): 688-92
103. Kawikova I, Barnes PJ, Takahashi T, et al. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am J Respir Crit Care Med 1996 Feb; 153 (2): 590-6
104. Taylor PC. Anti-tumour necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-9
105. Fernandez-Botran R, Crespo FA, Sun X. Soluble cytokine receptors in biological therapy. Expert Opin Biol Ther 2002; 2: 585-605
106. Weismann MH. What are the risks of biologic therapy in rheumatoid arthritis? an update on safety. J Rheumatol Suppl 2002; 65: 33-8
107. Black RA. Tumour necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002; 34: 1-5
108. Trifilieff A, Walker C, Keller T, et al. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2002; 135: 1655-64
109. Todd G, Dunlop K, McNaboe J, et al. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348: 27-9
110. Whol E, Majzoob J. Asthma, steroids and growth. N Engl J Med 2000; 343: 1113-4
111. Shacke H, Docke W-D, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43
112. Belvisi MG, Hele DJ. Soft steroids: a new approach to the treatment of inflammatory airways diseases. Pulm Pharmacol Ther 2003; 16 (6): 321-5
113. O'Connor B, Bonnaud G, Haahtela T. et al. Dose-ranging study of mometasone furonate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001 Apr; 86 (4): 397-404
114. Schmier J, Leidy NK, Gower R. Reduction in oral corticosteroid use with mometasone furonate powder inhaler improves health-related quality of life in patients with severe persistent asthma. J Asthma 2003 Jun; 40 (4): 383-93
115. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000; 1: 58-101
116. Taylor DA, Jensen MW, Kanabar V, et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-43
117. Dent G. Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002; 3: 78-83
118. Postma DS, Sevette C, Maninat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17: 1083-8
119. Drollmann A, Langdon C, Engelstatter R, et al. Ciclesonide is effective in the treatment of bronchial asthma [abstract]. Eur Respir J 2001; 18: P681
120. Weinbrenner A, Huneke D, Zschiesche M, et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002; 87: 2160-3
121. Pauwels RA, Derom E, Van de Velde V, et al. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients [abstract]. Am J Respir Crit Care Med 2002; 165: A768
122. Reid P. Roflumilast Altana Pharma. Curr Opin Investig Drugs 2002; 3: 1165-70
123. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10: 1361-79
124. Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis 2002; 57: 48-64
125. Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNFα ex vivo. J Clin Pharmacol 2002; 42: 297-303
126. Leichtl S, Schmid-Wirlitsch C. Dose-related efficacy of once-daily Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma [abstract]. Am J Respir Crit Care Med 2002; 165: A185
127. Kuss H, Hoefgen N, Johanssen S, et al. In vivo efficacy in airway disease models of AWD12-281, a selective PDE4 inhibitor for inhaled administration. J Pharmacol Exp Ther 2003 Oct; 307 (1): 373-85
128. Kumar RK, Herbert C, Thomas PS, et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 2003 Oct; 307 (1): 349-55
129. Carter AB, Monick MM, Hunninghake GW. Both erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 1999; 20: 751-8
130. Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000; 47: 185-201
131. Newton R, Holden N. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma. Biodrugs 2003; 17 (2): 113-29
132. Birrell M, Hele D, McCluskie K, et al. Effect of p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. Eur Respir J 2000; 16: 947-50
133. Underwood DC, Osborn RR, Kotzer CJ, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000; 293: 281-8
134. Irusen E, Matthews JG, Takahashi A, et al. p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57
135. Serhan CN, Devchand PR. Novel anti-inflammatory targets for asthma: a role for PPARγ? Am J Respir Cell Mol Biol 2001; 24: 658-61
136. Wang AC, Dai X, Luu B, et al. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001; 24: 688-93
137. Benayoun L, Letuve S, Druilhe A, et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med 2001; 164: 1487-94
138. Trifillieff A, Bench A, Hanley M, et al. PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-κB-independent model. Br J Pharmacol 2003 May; 139 (1): 163-71
139. Oates JC, Reilly CM, Crosby MB, et al. Peroxisome proliferator-activated receptor γ agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum 2002; 46: 598-605
140. Levy BD, Serhan CN. Exploring new approaches to the treatment of asthma: potential roles for lipoxins and aspirin-triggered mediators. Drugs Today (Barc) 2003 May; 39 (5): 373-84
141. Bonnans C, Vachier I, Chavis C, et al. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002; 165: 1531-5
142. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 2002; 8: 1018-23